318 related articles for article (PubMed ID: 28504999)
21. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
Hayano A; Komohara Y; Takashima Y; Takeya H; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Yamanaka R
Anticancer Res; 2017 Oct; 37(10):5655-5666. PubMed ID: 28982883
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 Status in Refractory Lymphomas.
Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
[TBL] [Abstract][Full Text] [Related]
23. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
24. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes.
Wang J; Gao K; Lei W; Dong L; Xuan Q; Feng M; Wang J; Ye X; Jin T; Zhang Z; Zhang Q
Oncotarget; 2017 Jan; 8(3):5414-5425. PubMed ID: 28036275
[TBL] [Abstract][Full Text] [Related]
25. Expression of programmed death-1 (CD279) in primary cutaneous B-cell lymphomas with correlation to lymphoma entities and biological behaviour.
Mitteldorf C; Bieri M; Wey N; Kerl K; Kamarachev J; Pfaltz M; Kutzner H; Roncador G; Tomasini D; Kempf W
Br J Dermatol; 2013 Dec; 169(6):1212-8. PubMed ID: 23937075
[TBL] [Abstract][Full Text] [Related]
26. Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
Aoki T; Hino M; Koh K; Kyushiki M; Kishimoto H; Arakawa Y; Hanada R; Kawashima H; Kurihara J; Shimojo N; Motohashi S
Pediatr Blood Cancer; 2016 Aug; 63(8):1461-4. PubMed ID: 27135656
[TBL] [Abstract][Full Text] [Related]
27. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes.
Burmeister K; Quagliata L; Andreozzi M; Eppenberger-Castori S; Matter MS; Perrina V; Grobholz R; Jochum W; Horber D; Moosmann P; Lehmann F; Köberle D; Ng CK; Piscuoglio S; Tornillo L; Terracciano LM
PLoS One; 2017; 12(4):e0175563. PubMed ID: 28403223
[TBL] [Abstract][Full Text] [Related]
30. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
31. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
[TBL] [Abstract][Full Text] [Related]
32. Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.
Xu T; Chai J; Wang K; Jia Q; Liu Y; Wang Y; Xu J; Yu K; Zhao D; Ma J; Fan L; Yan Q; Guo S; Chen G; Chen Q; Xiao H; Liu F; Qi C; Liang R; Li M; Wang Z
Front Oncol; 2021; 11():638154. PubMed ID: 34221962
[TBL] [Abstract][Full Text] [Related]
33. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
34. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
[TBL] [Abstract][Full Text] [Related]
35. Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis.
Cioroianu AI; Stinga PI; Sticlaru L; Cioplea MD; Nichita L; Popp C; Staniceanu F
Anal Cell Pathol (Amst); 2019; 2019():8586354. PubMed ID: 31934533
[TBL] [Abstract][Full Text] [Related]
36. IFN-γ decreased the suppressive function of CD33
Zhan X; Hu S; Wu Y; Li M; Liu T; Ming S; Wu M; Liu M; Huang X
Mol Immunol; 2018 Feb; 94():107-120. PubMed ID: 29291452
[TBL] [Abstract][Full Text] [Related]
37. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Kluger HM; Zito CR; Barr ML; Baine MK; Chiang VL; Sznol M; Rimm DL; Chen L; Jilaveanu LB
Clin Cancer Res; 2015 Jul; 21(13):3052-60. PubMed ID: 25788491
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression.
Choi JW; Kim YJ; Yun KA; Won CH; Lee MW; Choi JH; Chang SE; Lee WJ
Sci Rep; 2020 Sep; 10(1):14372. PubMed ID: 32873829
[TBL] [Abstract][Full Text] [Related]
39. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
40. Can cutaneous low-grade B-cell lymphoma transform into primary cutaneous diffuse large B-cell lymphoma? An immunohistochemical study of 82 cases.
Plaza JA; Kacerovska D; Sangueza M; Schieke S; Buonaccorsi N; Suster S; Kazakov DV
Am J Dermatopathol; 2014 Jun; 36(6):478-82. PubMed ID: 24698933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]